rs2317676 — ITGB3

GPIIIa 3'UTR — Platelet Activation Genetics and Antiplatelet Drug Response

Platelet glycoprotein IIIa (GPIIIa) — encoded by the ITGB3 gene on chromosome 17 — is the beta-3 subunit of integrin αIIbβ3, the most abundant receptor on platelet surfaces. When activated, this integrin binds fibrinogen and mediates platelet aggregation, the final common step in thrombus formation at sites of vascular injury. Integrin αIIbβ3¹¹ Integrin αIIbβ3
also called the fibrinogen receptor or CD41/CD61 complex; present at ~80,000 copies per platelet surface is the primary pharmacological target of antiplatelet drugs used in stroke and heart attack prevention.

The rs2317676 variant sits in the 3' untranslated region (3'UTR)²² 3' untranslated region (3'UTR)
the segment of mRNA downstream of the protein-coding sequence; contains regulatory elements including binding sites for microRNAs that control how much protein is produced from the mRNA of ITGB3. Unlike the well-known GPIIIa PlA2 variant (rs5918, L33P), which changes the protein's amino acid sequence, rs2317676 acts at the expression level — disrupting a microRNA-binding site in the 3'UTR and altering the amount of GPIIIa receptor protein produced. The G allele at this position disrupts normal microRNA regulation, increasing ITGB3 expression and potentially heightening platelet surface receptor density and platelet activation sensitivity.

The Mechanism

MicroRNAs (miRNAs) are short non-coding RNAs that bind complementary sequences in 3'UTR regions and suppress gene expression by blocking mRNA translation or promoting mRNA degradation. Ye et al. 2014³³ Ye et al. 2014
SNPs in microRNA-binding sites in the ITGB1 and ITGB3 3'-UTR increase colorectal cancer risk. Cell Biochem Biophys 2014 established that rs2317676 lies in a functional miRNA-binding site within the ITGB3 3'UTR. The G allele disrupts this binding site, impairing the miRNA's ability to suppress ITGB3 expression. The result is higher GPIIIa protein levels in cells expressing ITGB3 — most notably on platelets, where αIIbβ3 receptor density directly governs how readily platelets aggregate in response to activation signals.

Higher platelet αIIbβ3 expression amplifies the platelet response to thrombin, ADP, thromboxane A2, and other agonists. This creates a biologically plausible pathway to greater thrombotic risk and potentially reduced responsiveness to antiplatelet agents targeting upstream platelet activation pathways (aspirin targets thromboxane A2; clopidogrel targets P2Y12/ADP signaling; αIIbβ3 integrin itself is targeted by more potent agents like abciximab and eptifibatide).

The Evidence

Research on rs2317676 has focused primarily on gene-gene interaction studies in ischemic stroke patients — a context where individual variants rarely show large independent effects but combinations of platelet receptor polymorphisms produce clinically meaningful risk stratification. A series of studies by Yi et al. using ischemic stroke cohorts in China has consistently identified rs2317676 as a component of three-loci interactions that multiply individual variant effects.

Yi et al. 2019⁴⁴ Yi et al. 2019
The TXA2R rs1131882, P2Y1 rs1371097 and GPIIIa rs2317676 three-loci interactions may increase the risk of carotid stenosis in patients with ischemic stroke. BMC Neurology 2019 studied 614 ischemic stroke patients and found that carrying risk genotypes at all three platelet receptor loci — thromboxane receptor (TXA2R), ADP receptor (P2Y1), and GPIIIa (rs2317676) — produced a 2.72-fold increased risk of carotid stenosis (95% CI 1.28–7.82, p=0.001). The same group demonstrated that this three-locus combination was not explained by any single variant operating independently, suggesting true epistasis among platelet activation pathway components.

For antiplatelet therapy, Yi et al. 2020⁵⁵ Yi et al. 2020
Variants in clopidogrel-relevant genes and early neurological deterioration in ischemic stroke patients receiving clopidogrel. BMC Neurology 2020 found that a synergistic combination of CYP2C19*2 (rs4244285), P2Y12 (rs16863323), and GPIIIa (rs2317676) risk genotypes was associated with a hazard ratio of 2.82 (95% CI 1.36–7.76, p=0.003) for early neurological deterioration in 375 clopidogrel-treated stroke patients. Similar interaction findings involving rs2317676 were reported in the context of aspirin responsiveness and adverse events, as well as carotid plaque vulnerability in separate ischemic stroke cohorts.

The functional consequence (3'UTR miRNA binding site) is supported by the colorectal cancer association: the G allele's increased ITGB3 expression — relevant in an epithelial cell adhesion context — elevated colorectal cancer risk by OR 1.65 (95% CI 1.114–2.458) in an independent study, confirming that the variant has functional expression effects across tissues.

The evidence is classified as moderate: multiple independent studies support the association, a plausible biological mechanism exists, and the variant has been studied in clinical contexts (stroke, antiplatelet therapy). However, the studies are predominantly from single research groups using Chinese ischemic stroke cohorts, and the independent effects of rs2317676 versus combinatorial interactions have not been cleanly separated.

Practical Implications

For G-allele carriers, the most clinically relevant context is antiplatelet therapy. The evidence suggests that carrying this variant alongside other platelet pathway risk genotypes identifies a subgroup of stroke patients who experience reduced benefit from standard antiplatelet doses — either through pharmacological resistance (clopidogrel, aspirin) or through heightened platelet activation that overcomes these treatments. Platelet function testing (VerifyNow, PFA-100, light transmission aggregometry) can directly assess whether platelet inhibition is adequate in these patients.

Proactive knowledge of G-allele carrier status is particularly relevant for anyone who has had an ischemic stroke or TIA and is being managed with antiplatelet therapy, or anyone at elevated baseline thrombotic risk (atrial fibrillation, coronary artery disease, peripheral vascular disease).

Interactions

The most clinically significant aspect of rs2317676 is its interaction with other platelet activation pathway variants. Published compound effects involve: CYP2C19*2 (rs4244285) — reduced clopidogrel metabolism; P2Y12 (rs16863323) — ADP receptor subunit; P2Y1 (rs1371097) — ADP receptor subunit; TXA2R (rs1131882) — thromboxane receptor. Each of these independently contributes modest effects; in combination with rs2317676, the effects multiply. Individuals carrying risk genotypes at multiple platelet pathway loci represent the highest-risk group for antiplatelet therapy failure and adverse cerebrovascular events.

The rs5918 (PlA2, L33P) coding variant in the same ITGB3 gene is a distinct and well-established platelet antigen polymorphism that affects integrin receptor conformation and has been studied extensively in the context of cardiovascular events. rs2317676 and rs5918 tag different biological mechanisms (expression level vs. protein structure) and may act independently.